QuidelOrtho (NASDAQ:QDEL) and Navidea Biopharmaceuticals (NYSE:NAVB) Direct Analysis
QuidelOrtho (NASDAQ:QDEL – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both medical companies, but which is the better company? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
This table compares the net margins, return on equity and return on assets of QuidelOrtho and Navidea Biopharmaceuticals.
|Net margins||Return on equity||return on assets|
Valuation and benefits
This table compares gross revenue, earnings per share (EPS), and valuation of QuidelOrtho and Navidea Biopharmaceuticals.
|Gross revenue||Price/sales ratio||Net revenue||Earnings per share||Price/earnings ratio|
|QuidelOrtho||$1.70 billion||2.24||$704.23 million||$23.60||3.86|
|Navidea Biopharmaceuticals||$530,000.00||29.50||-$11.73 million||($0.39)||-1.32|
QuidelOrtho has higher revenue and profit than Navidea Biopharmaceuticals. Navidea Biopharmaceuticals trades at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
Institutional and insider ownership
92.9% of QuidelOrtho shares are held by institutional investors. By comparison, 5.6% of Navidea Biopharmaceuticals shares are held by institutional investors. 2.7% of QuidelOrtho stock is held by insiders of the company. By comparison, 32.4% of the shares of Navidea Biopharmaceuticals are held by insiders of the company. Strong institutional ownership indicates that endowments, hedge funds, and large fund managers believe a stock will outperform the market over the long term.
Volatility and risk
QuidelOrtho has a beta of 0.03, indicating its stock price is 97% less volatile than the S&P 500. In comparison, Navidea Biopharmaceuticals has a beta of 1.26, indicating its stock price is 26% more volatile than the S&P 500.
This is a summary of current recommendations for QuidelOrtho and Navidea Biopharmaceuticals, as provided by MarketBeat.
|Sales Ratings||Hold odds||Buy reviews||Strong buy odds||Rating|
|Navidea Biopharmaceuticals||0||0||0||0||N / A|
QuidelOrtho currently has a consensus price target of $98.67, indicating a potential upside of 8.42%. Given QuidelOrtho’s possible higher upside, analysts clearly believe that QuidelOrtho is more favorable than Navidea Biopharmaceuticals.
QuidelOrtho beats Navidea Biopharmaceuticals on 10 out of 13 factors compared between the two stocks.
(Get an evaluation)
QuidelOrtho Corporation provides various in vitro diagnostic products worldwide. The company’s product portfolio covers a range of point-of-care tests for infectious diseases, critical heart health and autoimmune biomarkers, as well as clinical and home products for detecting COVID-19. It provides visually readable lateral flow products in infectious disease and reproductive health; direct fluorescent antibodies in infectious diseases and virology; the production of microtitles with a focus on the bone pathway and complement markets; fluorescent immunoassays; molecular diagnostic products including Savanna, an integrated molecular diagnostic system; immunodiagnostics, clinical chemistry and integrated test systems to serve diagnostic laboratories of all sizes; immunodiagnostic donor screening systems and services that promote blood safety; pre-transfusion testing that automates blood bank workload with software to standardize operations, simplify tasks and improve productivity; and Ortho Care services and computer products. The company was founded in 1979 and is based in San Diego, California.
About Navidea Biopharmaceuticals
(Get an evaluation)
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapies. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company is developing the Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission tomography, positron emission tomography (PET), gamma scanning and intraoperative and/or optical fluorescence. detection, as well as the delivery of therapeutic compounds that target macrophages and immune and inflammatory diseases. It is developing NAV3-31, which has completed Phase IIb clinical trials to assess imaging repeatability, reproducibility and stability, as well as the capability of tilmanocept Tc99m imaging for the treatment of anti-factor therapy of alpha tumor necrosis in patients with moderate to severe rheumatoid arthritis. (AR); NAV3-35 which is in a phase IIb clinical trial for RA imaging; NAV3-33, which is in a phase III clinical trial for rheumatoid arthritis; and NAV3-32, which is a phase 2b trial for joints with RA. The company is also developing tilmanocept Tc99m for cardiovascular disease, Kaposi’s sarcoma, tuberculosis and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
Get news and reviews for QuidelOrtho Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for QuidelOrtho and related companies with MarketBeat.com’s FREE daily email newsletter.